Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

by Mariana Serpa, Sabri S. Sanabani, Israel Bendit, Fernanda Seguro, Flávia Xavier, Cláudia Bitti Barroso, Monika Conchon, Pedro Enrique Dorlhiac-Llacer
Published 2010-01-01